Phenotypic development of neocortical GABA neurons is highly plastic and promoted by various neurotrophic factors such as neuregulin-1. A subpopulation of GABA neurons expresses not only neuregulin receptor (ErbB4) but also epidermal growth factor (EGF) receptor (ErbB1) during development, but the neurobiological action of EGF on this cell population is less understood than that of neuregulin-1. Here, we examined the effects of exogenous EGF on immature GABA neurons both in culture and in vivo and also explored physiological consequences in adults. We prepared low density cultures from the neocortex of rat embryos and treated neocortical neurons with EGF. EGF decreased protein levels of glutamic acid decarboxylases (GAD65 and GAD67), and EGF influences on neuronal survival and glial proliferation were negligible or limited. The EGF treatment also diminished the frequency of miniature inhibitory postsynaptic currents (mIPSCs). In vivo administration of EGF to mouse pups reproduced the above GABAergic phenomena in neocortical culture. In EGF-injected postnatal mice, GAD-and parvalbumin-immunoreactivities were reduced in the frontal cortex. In addition, postnatal EGF treatment decreased mIPSC frequency in, and the density of, GABAergic terminals on pyramidal cells. Although these phenotypic influences on GABA neurons became less marked during development, it later resulted in the reduced b-and cpowers of sound-evoked electroencephalogram in adults, which is regulated by parvalbumin-positive GABA neurons and implicated in the schizophrenia pathophysiology. These findings suggest that, in contrast to the ErbB4 ligand of neuregulin-1, the ErbB1 ligand of EGF exerts unique maturation-attenuating influences on developing cortical GABAergic neurons.
The epidermal growth factor (EGF) family consists of EGF, transforming growth factor alpha (TGFa), amphiregulin, betacellulin, epiregulin, and heparin-binding EGF (HB-EGF), which all interact with the same EGF receptor, ErbB1 (Wong and Guillaud 2004; Iwakura and Nawa 2013) . These members of the EGF family have been extensively studied with respect to their roles on normal cell growth or oncogenesis in the periphery. In the central nervous system, the ErbB1 ligands HB-EGF and TGFa are expressed as their membrane-anchored pro-forms (Kaser et al. 1992; Lazar and Blum 1992; Kornblum et al. 1994; Nakagawa et al. 1998; Piao et al. 2005) . The production and release of their mature forms is markedly up-regulated by brain injury, ischemic stress, and seizure activity to promote neuroprotection and glial proliferation (Kawahara et al. 1999; Opanashuk et al. 1999; Liu et al. 2006; Oyagi et al. 2011; Oyagi and Hara 2012) . In contrast to HB-EGF and TGFa, synthesis of EGF is relatively limited in the brain (Fallon et al. 1984) . However, EGF is present and pathologically induced in amniotic fluids as well as in blood (Connolly and Rose 1988) . In prenatal and perinatal stages, EGF circulating in the periphery can cross the blood-brain barrier and perturbs neuronal development, especially in early developmental stages (Pan and Kastin 1999; Futamura et al. 2003; Tohmi et al. 2005; Yokomaku et al. 2005; Namba et al. 2006; Nagano et al. 2007) . Accordingly, EGF and other members in the EGF family are suggested to play neuropathological roles in psychiatric diseases of developmental origin (Mizuno et al. 2007; Suzuki et al. 2007; Toyoda et al. 2007; Tsuda et al. 2008; Nawa et al. 2014) .
The members of the EGF family directly and indirectly act on neurons to enhance neuronal survival and neurite extension (Morrison et al. 1987; Yamada et al. 1995; Ferrari et al. 1999; Kornblum et al. 1999) . Among various cortical neurons, the receptor ErbB1 is expressed in young GABAergic neurons and the expression of ErbB1 diminishes during development (Fox and Kornblum 2005; Nagano et al. 2007; Abe et al. 2009 ). Systemic administration of EGF to mouse neonates affects synaptic development of GABAergic neurons by reducing a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (Nagano et al. 2007 ) and scaffolding proteins for these receptors (Yokomaku et al. 2005 ). An EGF-like ligand, neuregulin-1 (NRG1), which acts on another ErbB receptor, ErbB4, positively regulates the development of excitatory and inhibitory synapses and is implicated in schizophrenia neuropathology (Woo et al. 2007; Vullhorst et al. 2009; Fazzari et al. 2010; Abe et al. 2011; Ting et al. 2011; Del Pino et al. 2013; Yang et al. 2013) . In contrast to the knowledge of NRG1 actions, neuropathological roles of EGF/ErbB1 activity are poorly understood in this neuronal population.
In this study, we assessed the effects of EGF on developing GABA neurons using primary neocortical cultures. After evaluating the EGF actions in culture, we also validated that the observed EGF actions were reproducible in vivo. To mimic ErbB1 stimulation in the brain, we challenged mice pups with EGF by subcutaneously injecting EGF daily. Phenotypic influences on GABA neurons were evaluated by immunochemical and electrophysiological approaches. With the present experimental results, we discuss the neuropathological implication of the EGF activity in comparison with the reported actions of NRG1.
Materials and methods

Animals
Time-pregnant rats (Sprague-Dawley) were purchased from SLC (Shizuoka, Japan) and used for the cell culture study. For in vivo EGF administration, newborn mice (C57BL/6N; postnatal day 2) or pregnant mice in late gestation were purchased from SLC. Animals were maintained under a 12-h light/dark cycle with free access to food and water. Recombinant human EGF (Higeta-Shoyu, Chiba, Japan) was dissolved in physiological saline and administered subcutaneously to mouse pups of both sexes from postnatal day 2-10 on the nape of the neck at a dose of 875 ng/g of body weight. Control littermates received injections of cytochrome c (Sigma, St Louis, MO, USA) at the same dose with EGF. All of the animal experiments described were approved by the Animal Use and Care Committee of Niigata University and performed in accordance with NIH guidelines.
Rat neocortical culture
Whole cerebral neocortices of embryonic rats (embryonic day 18-19) were digested with papain (1 mg/mL, Sigma), mechanically dissociated and grown on poly-D-lysine-coated dishes at a density of 100-200 cells/mm 2 with serum-free medium (Nagano et al. 2007 ). EGF (20 ng/mL) was added daily to the cultures from 2 days in vitro (DIV). All biochemical and cytological examinations were done around 5-6 DIV before glial proliferation became detectable (see Fig. 1 ). EGF treatment, however, was extended until 7-11 DIV for GABA immunohistochemistry and electrophysiological recording. Note that higher cell densities (> 200 cells/mm 2 ) or nonmechanical dissociation allowed glial proliferation and hampered the present assay (data not shown).
Western blotting
Cultured cortical cells or brain tissues of the frontal cortex were lysed in Laemmli sample buffer (10% glycerol, 2% sodium dodecyl sulfate, 65 mM Tris) (Nagano et al. 2007) . Equal amounts of protein samples (1, 20, or 30 lg/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) with 1 mm-thick polyacrylamide slab gels. The separated protein was transferred to a nitrocellulose or polyvinylidene fluoride membrane by electrophoresis. The membrane was then incubated with the following primary antibodies: anti-glutamic acid decarboxylase (GAD)65/67 (1 : 5000, Sigma, RRID: AB_477019), anti-GAD67 (1 : 2000, Merck Millipore, Darmstadt, Germany, RRID: AB_2278725), anti-parvalbumin (1 : 3000, Abcam, Cambridge, UK, RRID: AB_298032), anti-GFAP (1 : 4000, DakoCytomation, Glostrup, Denmark, RRID: AB_10013382), anti-c enolase (neuron specific enolase) (1 : 5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA, RRID: AB_627513) and anti-b-actin (1 : 500, Cell Signaling, Danvers, MA, USA, RRID: AB_2223041) antibodies. After extensive washing, the membrane was reacted with goat antirabbit or mouse immunoglobulin conjugated to peroxidase (1 : 10 000). Immunoreactivity of the blots was visualized by a chemiluminescence reaction combined with film exposure (Western Lighting, PerkinElmer, Waltham, MA, USA). Quantitative densitometric analyses of immunoblots were performed by Image J software (NIH, Bethesda, MD, USA).
Immunocytochemistry
Cultured cells were fixed with 4% paraformaldehyde, 0.5% glutaraldehyde, and 2% sucrose in 0.15 M phosphate buffer. After extensive washing, cells were incubated with an anti-GAD antiserum (1 : 100, Sigma) or anti-GABA antibody (1 : 2000, Sigma, RRID: AB_477652). After washing, cells were incubated with Alexa546 goat anti-rabbit IgG (1 : 500, Molecular Probe, RRID: AB_143051). Five microscopic fields (0.04 mm 2 ) from each culture dish were randomly selected. The GAD-immunopositive area, which displays fluorescence intensity of more than 60/256 in the intensity histogram, was calculated using Scion image (Scion Corporation, Frederick, MD, USA) and normalized by the number of cells per field. Results were then normalized to control values. Alternatively, the GABA-immunopositive puncta, which harbored fluorescence intensity of more than 15/256 in the digital intensity histogram, were isolated and analyzed by the image software (BZ-II analyze, Keyence, Osaka, Japan) and normalized by the number of GABA-positive neurons in individual picture fields. The glia-like cells, which lacked GABA-positive neurites, were excluded from the analysis.
Alternatively, cultured cells were immunostained for MAP-2 (1 : 300, mouse; Merck Millipore, RRID: AB_91939) with Vectastain ABC elite kit (Vector Laboratories, Burlingame, CA, USA). Six microscopic fields (0.09 mm 2 ) from each culture dish were randomly selected. The MAP-2-immunopositive soma area was calculated using the Scion image software (Scion Corporation). For cell counting, the number of immunopositive neurons was counted in 20 randomly chosen areas (0.09 mm 2 ) from four dishes under a bright-field microscope. All images were taken by a fluorescence microscope (Axioscop, Zeiss, Jena, Germany) with an 940 objective lens (Zeiss) and a digital camera (DP50-CU; Olympus, Tokyo, Japan).
Whole-cell recording of spontaneous synaptic activity in neocortical culture Spontaneous mIPSCs were recorded in culture from morphologically identified pyramidal cells by the whole-cell patch-clamp technique at 23-25°C as described previously (Nagano et al. 2007) . Electrical properties of a recorded cell were determined by measuring the current change in response to a negative 5 mV (100 ms) pulse from a holding potential of À78 mV. mIPSCs were recorded at a holding potential of 0 mV in the presence of 1 lM tetrodotoxin (TTX) (Wako, Osaka, Japan), 10 lM 6-cyano-7-nitroquinoxaline dione (CNQX) (Tocris Biosciene, Bristol, UK) and 50 lM DL-2-amino-5-phosphonopentanoic acid (DL-AP5) (Tocris Bioscience). Data acquisition and processing were performed with an Axopatch 200B amplifier and a Digidata 1200 digital converter (Molecular Devices, Sunnyvale, CA, USA) as described previously (Nagano et al. 2007) . Miniature synaptic events were detected and analyzed by Mini Analysis software (Synaptosoft, Leonia, NJ, USA).
Immunohistochemistry
Mouse pups at postnatal day 11 were deeply anesthetized with halothane and killed by transcardiac perfusion with 4% paraformaldehyde in a 0.1 M phosphate buffered solution. After post-fixation and cryoprotection with 30% sucrose, the brain tissues were embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, CA, USA). Coronal sections (20 lm thickness) of the frontal cortex, located anteriorly within 300 lm from the genu of the corpus callosum (Franklin and Paxinos 2008) , were prepared and stored at À80°C until use.
For immunostaining, sections were incubated overnight with a primary antibody [anti-parvalbumin polyclonal antibody (1 : 5000, Abcam) or anti-GAD67 monoclonal antibody (1 : 5000, Merck Millipore)] at 4°C. After incubations with a secondary biotinylated Fig. 1 Effects of epidermal growth factor (EGF) on GAD proteins in cultured cortical neurons. (a) Typical blotting images of neocortical culture at 5-6 days in vitro (DIV) are shown. Low density cultures were prepared from embryonic rat neocortices and grown for 5-6 days in a serum-free condition in the presence or absence of EGF. (b) Densitometric quantification of protein expression (n = 4 cultures each) is plotted. The mean levels in control cultures were set at 100%. *p < 0.05, ***p < 0.001, Student's t-test.
antibody for 2 h at 23-25°C (1 : 200 for rabbit IgG, RRID: AB_2313606, or 1 : 500 for mouse IgG, RRID: AB_2313581, Vector Laboratories) and Vectastain ABC elite kit (1 : 100, Vector Laboratories) for 1 hr at 23-25°C immunoreactivity was visualized with diaminobenzidine in the presence of H 2 O 2 .
To determine the numbers of GAD67-or parvalbumin-immunoreactive cells, photomicrographs of the frontal cortex (Franklin and Paxinos, 2008) were photographed by a digital microscope (BZ-9000, Keyence, Osaka, Japan) and analyzed with its application software (BZ-II analyze, BZ-H2A, Keyence). Since GAD67 protein is expressed in both somata and terminals during postnatal development (Kiser et al. 1998) , GAD67-immunopositive somata were visually identified in layer 2/3 and layer 5 of the primary motor area of the frontal cortex (500 9 375 lm square each) and counted. Highly parvalbumin immunoreactive cells and moderately immunopositive cells were counted using Dynamic cells count software (BZ-H1C, Keyence). To isolate highly immunoreactive cells, the detection level of the intensity histogram was set at the grayscale level of 100/256 for all digital photomicrographs. The cell densities in both hemispheres were averaged for each section.
Confocal microscopy
To measure the number of vGAT-immunoreactive puncta around pyramidal neurons, the brain sections were stained with anti-vGAT rabbit polyclonal antibody (1 : 1000, Frontier institute, Ishikari, Japan, RRID: AB_2571622) and anti-non-phospholyrated neurofilament H mouse monoclonal antibody (SMI-32;1 : 1000, Merck Millipore, RRID: AB_2043449) (Horie et al. 2015) . Immunoreactivities were visualized with the secondary antibodies of anti-rabbit IgG Alexa 488 (1 : 200, Abcam, RRID: AB_2630356) or antimouse IgG Alexa 568 (1 : 200, Molecular probe, RRID: AB_141371).
Scanned microscopic images of SMI-32-immunopositive cells were taken from layer 5 of mouse frontal cortex using a confocal laser scanning microscope (1024 9 1024 pixel with a 609 oil immersion objective for FV-1200, Olympus). Five to six optical sections (2 lm interval for z distance) were scanned through cortical sections. Individual optical sections were examined to count the number of peri-somatic puncta on the surface of each pyramidal neuron.
Whole-cell patch-clamp recordings Briefly, neonatal brains at postnatal day 10 and 11 were removed and two pairs of coronal hemi-slices of the frontal cortex at the anterior edge of the striatum (thickness: 200 lm) were prepared with a microslicer (Pro7, Dosaka, Kyoto, Japan) (Nagano et al. 2007 ). Whole-cell patch-clamp recordings were made from the pyramidal cells located in layer 2/3 or layer 5 of the frontal cortex (Franklin and Paxinos 2008) . Spontaneous mIPSCs were recorded at a holding potential of 0 mV in the presence of 1 lM TTX (Wako), 10 lM CNQX (Tocris Bioscience) and 50 lM DL-AP5 sodium salt (ab1202871, Abcam). Recordings with a series resistance of more than 20 MΩ or in which the series resistance changed by more than 15% were excluded. Miniature events with the amplitudes of more than 6 pA were detected and analyzed by Mini Analysis software (Synaptosoft). One hundred miniature events were pooled and analyzed for the mean frequency and amplitude of each cell. To measure paired-pulse ratios of evoked IPSCs in layer 5 pyramidal neurons, a microconcentric bipolar stimulating electrode was placed 300-400 mm beneath the recording position. Paired-pulse IPSCs (interstimulus intervals, 25-200 ms) were triggered with electric stimuli (0.5 mA, 50 ls) at 0.05 Hz in the presence of 10 lM CNQX (Tocris Biosicence) and 25 lM DL-AP5 sodium salt (Abcam).
Surface electroencephalogram
Mice (both sexes at postnatal 14-15 weeks) were anesthetized with sodium pentobarbital (Somnopentyl; 65 mg/kg, i.p., Kyoritsu, Tokyo, Japan) and placed in a stereotaxic apparatus (SR-6M, Narishige, Tokyo, Japan). Three stainless screws were implanted in the right frontal cortex (1.7 mm anterior and 1.3 mm lateral to bregma; an active electrode), in the right frontal sinus (5.0 mm anterior and 0.3 mm lateral to bregma; a reference electrode) and in the left cerebellum (1.5 mm posterior and À1 mm lateral to lambda for ground). After a 2 week recovery period from surgery, electroencephalogram recording was performed in a home cage placed in a sound-sealed chamber (San Diego Instruments, San Diego, CA, USA). After acclimation, the animals were exposed to click sounds one hundred times (85 dB, 10 ms duration, 6 s intervals) with background white noise of 70 dB (Long et al. 2015) .
Signals from the active electrode were amplified and band-pass filtered at 0.5-1000 Hz using an amplifier (DAM-80, World Precision Instruments, Sarasota, FL, USA). The amplified signals were digitized at 10 kHz (Digidata1200B, Molecular Devices) and analyzed by Spike2 software (Cambridge Electronic Design, Cambridge, UK).
For wavelet analysis of evoked potential, data were analyzed by the SciLab wavelet tool box (http://scwt.sourceforge.net/). Mean power was calculated for each frequency band and inter-trial phase coherence was computed between À2 and +2 s from the stimulus onset. Inter-trial phase coherence ranged from 0 (non-phase-locked, random activity) to 1 (fully phase-locked across individual trials). Alternatively, the power of spontaneous activities was analyzed using fast Fourier transformations (Hamming window, 0.31 Hz resolution). Relative power in each frequency band was calculated as the ratio of the raw power of the band to the total power (0.5-100 Hz) (Long et al. 2015) .
High performance liquid chromatography
For the measurement of tissue GABA content in vivo, frontal cortex was dissected and frozen in dry ice and stored at À80°C until analysis. The frozen sample was collected into 0.1 M perchloric acid, homogenized and then centrifuged at 20 000 g for 10 min at 4°C. The supernatant was used directly for amino acid analysis. The pellet was used for total protein quantification. Tissue GABA content was measured via an electrochemical method, a pre-column derivatization of GABA with fluoraldehyde, as described elsewhere (Reynolds and Beasley 2001) . The mobile phase consisted of 0.10 M CH 3 COONa, 0.12 mM Na 3 EDTA and 15-50% acetonitrile (pH 5.6). GABA concentrations were calculated from the peak values and expressed as the percent of control.
Study design and statistical analysis Sample assignment to groups was not randomized and data analyses were not blinded in this study. Data are expressed as means AE SEM. Univariate data with small sample sizes were analyzed by Student's t-test and analysis of variance (ANOVA) to assess statistical differences between and among experimental groups, respectively. Non-parametric data such as electrophysiological results were subjected to the non-parametric Mann-Whitney U test and/or Kolmogorov-Smirnov test. A p value of less than 0.05 was considered statistically significant.
Results
Negative effects of EGF on GAD65/67 expression in cultured neocortical neurons Neocortical cultures were prepared from embryonic rats and grown in serum-free conditions in the presence of EGF from 1 to 5 or 6 DIV. Western blotting revealed that EGF treatment decreased protein levels of glutamic acid decarboxylases (GAD65 and GAD67), which synthesize GABA from glutamate (Kakizaki et al., 2015) . In contrast, b-actin protein levels and glial fibrillary acidic protein (GFAP) levels were not affected (Fig. 1) . The EGF effects on GAD proteins were fully reversed by the addition of an ErbB1 kinase inhibitor, Tarceva (Fig. S1 ). Total amounts of protein recovery per dish were not influenced, suggesting that the influence of EGF on cell proliferation was limited in the present culture condition.
To confirm whether the changes in total levels of GAD proteins represent a decrease in its cellular content per cell, cultured cortical neurons were immunostained with an anti-GAD65/67 antibody (Fig. 2) . In control condition, we found significant GAD immunoreactivity in soma area of cultured neurons. When the cortical neurons were treated with EGF, however, the intensity of GAD immunoreactivity was diminished without altering the total number of the GADpositive cells (Fig. 2a-d) . EGF had no gross effect on the overall neuronal population either, as revealed by microtubule-associated protein-2 immunostaining (Fig. 2e-h ). These results suggest that EGF attenuates the GAD expression without influencing gross survival and/or cell growth of cultured neurons.
Reduction in GABA-containing vesicles in EGF-treated culture How does EGF treatment qualitatively and quantitatively affect the formation and/or maturation of GABA-containing vesicles? To estimate the effects on GABA-containing vesicles, we counted the number of GABA-immunoreactive puncta and measured the intensity of GABA immunoreactivity in individual puncta in DIV7 cortical cultures. To compare the number and intensity of GABA-positive puncta, the intensity histogram was plotted (Fig. 3) . EGF treatment significantly reduced the number of GABA-positive puncta (F 1,69 = 61.7, p < 0.001 by ANOVA) with the present detection threshold. The intensity distributions of GABA immunoreactivity of the EGF-treated cultures were shifted to low (i.e. toward left in Fig. 3 ) (U = 480820, p < 0.001 Mann-Whitney U-test). With the given technical limitation, however, we cannot rule out the possibility that the reduction in the number of GABA-positive puncta might result from the decrease in the strength of their GABA immunoreactivity or tissue GABA content (see below).
Suppression of inhibitory miniature currents in EGF-treated neocortical cultures
The whole-cell patch-clamp approach was applied to monitor the strength of GABAergic synaptic transmission in culture (Fig. 4) . The culture term was extended until 10-11 DIV to allow synapse formation and maturation, although the culture extension also allowed glial cells to proliferate (data not shown). EGF treatment significantly reduced the mean frequency of the mIPSCs in neocortical culture (p < 0.01) ( Fig. 4a and c) . In spite of lower series resistance in EGFtreated cells (Table 1) , the mean amplitude of mIPSCs was not altered by EGF (p = 0.51) (Fig. 4b) . Other electrical properties, such as the input resistance and membrane capacitance, were not altered (Table 1 ). These observations suggest that chronic treatment with EGF alters inhibitory synaptic function and/or GABAergic synapse formation in primary neocortical culture.
Neurochemical impact of in vivo EGF administration
To assess in vivo effects of EGF, EGF was administered subcutaneously to pups from postnatal day 2-10. EGF is known to penetrate the blood-brain barrier during early postnatal stages of rats and mice (Kleshcheva 1988; Futamura et al. 2003; Tohmi et al. 2005) . Phenotypic effects of EGF on GABAergic neurons were examined by immunohistochemistry for GAD67 in cortical layer 2/3 and layer 5 of the frontal cortex (Fig. 5) . EGF administration decreased the frequency of GAD67-immunoreactive cells to 88 AE 4% of control (p < 0.05) in layer 5 (Fig. 5a and b, e-g ) but the reduction in layer 2/3 failed to reach the significance range (Fig. 5a-d and g ). In parallel, western blotting reveals significant decreases in total levels of GAD65 and GAD67 proteins (Fig. 5h) . We also detected a significant decrease in GABA content in the frontal cortex of EGF-treated mice (control: 100 AE 11% (n = 5 animals); EGF: 48 AE 7% (n = 6 animals), p < 0.01; Student's t-test). These results indicate that EGF attenuates GABA synthesis in vivo, resulting from the phenotypic reduction in GAD67-expression.
EGF is known to down-regulate the glutamate receptors expression in the subpopulation of GABA neurons that particularly contains parvalbumin (Nagano et al. 2007) . Since the expression of parvalbumin is very low in the early postnatal stage and gradually elevates during development (D avila et al. 2005) , we examined the mice on postnatal day 11 or at more late stages and compared parvalbumin immunoreactivity in the frontal cortex of EGF-treated mice (Fig. 6 ). There were decreases in the frequency of heavily parvalbumin-labeled cells (39 AE 7%. p < 0.001 in layer 2/3 and 74 AE 7%. p < 0.01 in layer 5) in EGF-treated mice ( Fig. 6c-g ). In contrast, the frequency of moderately parvalbumin-positive cells was not affected or increased (layer 2/3: p = 0.17; layer 5: p < 0.05) (Fig. 6h) . The total number of parvalbumin-positive cells in both layers was not affected (control: 157 AE 5, EGF: 140 AE 5 cells/mm 2 in layer 2/3, p = 0.14; control: 134 AE 3, EGF: 140 AE 5 cells/mm 2 in layer 5, p = 0.32). Western blotting supported this immunohistochemical finding; total protein levels of parvalbumin were reduced in the frontal cortex of EGF-treated mice (Fig. 6i) . Of note, a modest but statistically significant EGF effect on parvalbumin was persistent until the juvenile stage (data not shown).
Influences of EGF administration on GABAergic synapses
Do EGF signals also influence synaptic functions in vivo as observed in primary culture? To address this question, spontaneous mIPSCs were recorded from layer 5 pyramidal neurons in cortical slices of EGF-treated mice (Fig. 7) . The frequency of mIPSCs was significantly diminished in the EGF group, whereas their amplitude was not altered. Kolmogorov-Smirnov test confirmed the change in mIPSC frequency (p < 0.001). The membrane capacitance of the pyramidal neurons was significantly decreased (p < 0.05) although other electrical properties were not affected ( Table 2 ). The same electrophysiological trends were observed in layer 2/3 as well (data not shown).
Did the mIPSC decrease reflect the reduction in functional synaptic numbers or that in presynaptic GABA release probability? To distinguish these possibilities, we carried out the electrophysiological experiment of paired pulse facilitation (Fig. 7b) . In any intervals, paired pulse ratios of IPSCs were indistinguishable in layer 5 pyramidal neurons, suggesting that EGF treatment did not alter the probability of GABA release. To test the alternative possibility, we compared the presynaptic densities of GABA terminals between EGF-treated and non-treated mice. We marked the GABA terminals with the anti-vGAT antibody and labeled the somata of pyramidal neurons with the SMI-32 antibody, which recognizes non-phosphorylated neurofilament protein (Fig. 8) . In particular, parvalbumin-positive GABA neurons often form presynaptic terminals on somatic regions of the layer 5 pyramidal neurons (Chattopadhyaya et al. 2004; Kubota et al. 2016) . Confocal microscopy observation revealed that the numbers of perisomatic puncta around the pyramidal neurons were significantly decreased by EGF treatment. This finding suggests that EGF treatment diminished the number of perisomatic GABAergic terminals around pyramidal neurons.
An abnormality in electroencephalogram of EGF-treated mice
The functional deficits of cortical GABA neurons are known to disrupt the higher frequency bands of electroencephalogram (Buzs aki and Wang 2012) . Especially, parvalbuminpositive GABA neurons are implicated in the phase locking of gamma range oscillations (Sohal et al. 2009; Nakamura et al., 2015) . To explore the pathophysiological consequences of the observed EGF-driven GABA deficits, we measured event-related responses of the adult EGF-treated mice to auditory stimulation (Fig. 9) . The calculated power of event-related responses in the beta (12-30 Hz) and gamma (30-80 Hz) ranges was significantly diminished in EGF-treated mice (Fig. 9b) . In contrast, the calculated power of delta (1-4 Hz) to alpha ranges (8-12 Hz) resulted in no significant differences between groups. Inter-trial phase coherence of the peak responses was simultaneously decreased in the beta and gamma ranges. However, there were no differences in spontaneous electroencephalogram activities in the absence of sound stimuli (data not shown). These results suggest that EGF-treatment during neonatal stage perturbed the phase-locking potentials in the beta-and gamma-ranges and thus their total powers were reduced in electroencephalogram.
Discussion
The EGF receptor ErbB1 is expressed in a subpopulation of GABAergic neurons, in particular, young parvalbuminpositive GABA neurons (Seroogy et al. 1995; Kornblum et al. 1999; Fox and Kornblum 2005; Abe et al. 2009 ). In the present study, we focused on cortical GABAergic neurons as one of the cellular targets for EGF and characterized the pathological responses of this neuronal population to exogenous EGF during development. In neocortical culture from rat embryos as well as in early postnatal mice, we found that (1) subchronic treatment with EGF decreased the expression of GAD65 and/or GAD67 as well as the number of GABA-containing vesicles and GABA contents. (2) The frequency of mIPSCs was reduced in EGF-treated cultures and in the frontal cortex of EGF- Fig. 3 Epidermal growth factor (EGF) effects on GABA-containing vesicles in neocortical culture. Primary neocortical cultures were grown in the presence (b) or absence (a) of EGF for 7 days and then immunostained with anti-GABA antibodies. Typical images of GABA immunostaining are shown. (c) GABA-positive puncta (red) in these digital images were isolated and the fluorescent intensities of individual puncta (i.e. 8 bit = 256 levels) were measured by the image software (see details in Methods). GABA-positive puncta were isolated with the pixel intensity threshold of 16/256, and their number was counted and plotted against their fluorescent intensity bins. The intensity and frequency distributions of GABA-positive puncta were separately compared by ANOVA and Mann-Whitney U-test between groups, respectively (n = 1619 puncta for control and n = 769 puncta for EGF group; 5 microscopic fields from 4 sister cultures for each group). To display the weak GABA immunoreactivity in control cultures, its signal intensity is equally elevated in both panels (a) and (b). Scale bar, 50 lm. treated mice. (3) In vivo EGF administration during the neonatal period decreased GABA content and phenotypic GABA markers in the frontal cortex. (4) The auditoryevoked electroencephalogram powers of gamma and beta bands and their inter-trial phase coherences were both decreased in EGF-treated mice at their adult stage. These findings suggest that this cytokine EGF, and potentially other ErbB1 ligands, have the unique biological activity that attenuates phenotypic and functional development of cortical GABAergic neurons and functions. The activity of EGF observed in GABAergic neurons contrasts with the activity of the other neurotrophic factors such as brain-derived and neurotrophic factor, glial cell line-derived neurotrophic factor, and neuregulin-1, all of which can promote differentiation and maturation of GABAergic neurons (NarisawaSaito et al. 1999; Namba et al. 2006; Canty et al. 2009; Suzuki et al. 2014) .
In healthy conditions, however, the influence of endogenous ErbB1 signals is presumably modest with the given limitation of endogenous EGF and basal phosphorylation levels of ErbB1 in the brain (Tohmi et al. 2005) . However, it is well known that the brain insults such as ischemia, inflammation, and blood-brain barrier breakdown recruit ErbB1 signaling from EGF or other ErbB1 ligands (Kawahara et al. 1999; Opanashuk et al. 1999; Liu et al. 2006; Oyagi et al. 2011; Oyagi and Hara 2012) . In this context, the maturation-attenuating activity of EGF might be recruited in such pathological conditions. Whether such EGF/ErbB1 signals at the adult stage indeed exerts the same effects on GABAergic neurons remains to be explored, however.
Maturation attenuating activity of ErbB1 ligands on developing GABAergic neurons
This study reveals that EGF has the maturation-attenuating activity, which down-regulates the expression of GAD65/67 and the maturation of GABA-containing vesicles. Cortical GABA neurons can be classified into distinct subpopulations marked with different proteins (Kubota et al. 2011) . In EGFtreated cultures, we found a marked decrease in parvalbumin immunoreactivity, but not in other marker proteins for GABAergic neurons such as neuronal nitric oxidase and calbindin D (data not shown). Thus, the cellular target of the EGF action appeared to be limited among various types of GABAergic neurons in the neocortex (Kubota et al. 2011 (Kubota et al. , 2016 .
The observed activities of EGF are in accordance with the facts that parvalbumin-positive GABAergic neurons are 
Control (n = 9) 22.8 AE 2.3 482 AE 67 29.4 AE 2.6 EGF (n = 9) 18.1 AE 1.1* 590 AE 73 34.6 AE 2.7
Whole-cell patch-clamp recordings were made from pyramidal-shaped neurons in primary neocortical cultures at 10 and 11 DIV. The series resistance was significantly diminished by EGF treatment. *p < 0.05, Mann-Whitney U test. Rs, series resistance; Rm, membrane resistance; Cm, membrane capacitance. Mean AE SEM.
enriched with ErbB1 and reactive to EGF to decrease AMPA-type glutamate receptors levels (Fox and Kornblum 2005; Nagano et al. 2007) . It is known that EGF promotes cell survival of neocortical neurons (Morrison et al. 1987) . Our previous histopathological examinations failed to detect any sign of neurodegeneration in the neocortex of EGFtreated rat pups (Futamura et al. 2003) . These observations presumably limit the contribution of cell death to the reduction in the cell density of GAD-positive or parvalbumin-positive neurons.
Although we suggest that the present neurochemical phenomena are likely to represent the responses of the GABAergic neurons to EGF, we do not fully rule out the potential contribution of the glia-mediated indirect action of EGF on this neuronal population (Burrows et al. 1997; Gao et al. 2014) . However, the induction of reactive astrocyte marker GFAP was limited in our short-term cultures as well as in vivo (Futamura et al. 2003; Yokomaku et al. 2005) . Alternatively, it might be possible that EGF influenced glial functions and/or neuronal excitability, leading to the present phenotypic changes (Marty et al. 2000; Patz et al. 2003) . In this context, it remains to be characterized how EGF regulates the neuron-glia interactions to influence the phenotypic development of GABAergic neurons.
The activity of the ErbB1 ligand EGF contrasts with that of the ErbB4 ligand neuregulin-1 The ErbB4 ligand of NRG1 (a homolog of EGF) is known to specifically promote GABAergic development and neurotransmission (Woo et al. 2007; Kato et al. 2010; Abe et al. 2011; Ting et al. 2011; Yang et al. 2013) . For example, NRG1 signals elevate glutamate receptor expression to enhance excitatory inputs to developing GABAergic neurons (Gu et al. 2005; Abe et al. 2011) . In spite of the numerous findings on such positive regulators, the information of negative regulators has been quite limited. In this context, it is noteworthy that the observed negative action of EGF markedly contrasts with the reported NRG1 actions on the same neuronal population, even though both factors belong to the same EGF gene family and interact with the same (g and h) Quantitative analysis reveals that the densities of highly immunoreactive cells in layers 2/3 and 5 are diminished by EGFadministration (g), whereas moderately immuno-positive cells are not altered or increased (h) (n = 25 sections for 5 animals each). The cutoff range of 'high' immunoreactivity was set to 100/256 of the 8-bit intensity histogram for all digital photomicrographs. (i) Decreased parvalbumin protein in frontal cortex. EGF was subcutaneously administered each day until postnatal day 14 and brain tissues were sampled at postnatal day 15. Typical blotting images for parvalbumin (PV) and NSE are shown. The intensity of PV immunoreactivity is normalized with that of NSE and their ratios are plotted (n = 6 animals each). *p < 0.05, **p < 0.01, ***p < 0.001, Student's t-test. 
Psychopathological implication of EGF actions on GABAergic neurons
In the postmortem prefrontal cortex of schizophrenia patients, the expression of parvalbumin is known to be decreased although the densities of parvalbumin-positive neurons are maintained (Hashimoto et al. 2003; Lewis and Hashimoto 2007) . The reduction in parvalbumin mRNA levels is most marked in layers 3 and 4 but not in layers 5 and 6 (Hashimoto et al. 2003; Lewis and Hashimoto 2007) . In addition, this parvalbumin reduction is less pronounced in other cortical areas (Cotter et al. 2001) . Considering the postnatal induction of parvalbumin expression, Reynolds and Beasley (2001) proposed the hypothesis that GABAergic . The number of perisomatic-puncta was counted in individual pyramidal neurons (i.e. 10-18 somata in each section, n = 16 sections in total). In cumulative probability plots, the number of vGAT-immunopositive puncta contained by each pyramidal neuron was plotted on a X-axis and the frequency of the pyramidal neurons containing that number of the puncta was plotted on a Y-axis. The plots confirm the decrease in the number of perisomatic puncta in EGF-pretreated mice. ***p < 0.001, Kolmogorov-Smirnov test. deficits in schizophrenia may stem from toxic events occurring during cortical development which selectively target immature neurons before protection by parvalbumin is conferred. The present model of EGF signaling might fit into this hypothesis (Mizuno et al. 2004; Tohmi et al. 2005; Tsuda et al. 2008; Sotoyama et al. 2013; Nawa et al. 2014; Sakai et al. 2014) . Many reports suggest a biological link between schizophrenia and impaired GABAergic functions (Benes et al. 1991; Akbarian et al. 1995; Lewis et al. 2005; Behrens and Sejnowski 2009; Fukuda and Wang 2013) . The auditoryevoked gamma oscillation of electroencephalogram, which is mainly regulated by cortical GABA neurons, is disrupted in patients with schizophrenia (Sohal et al. 2009; Buzs aki and Wang 2012; Hirano et al. 2015) . In agreement, the power of the gamma-range electroencephalogram of EGF-treated mice was decreased with their disruption of inter-trial phase coherence. Although we failed to detect marked abnormality in GABA-or parvalbumin-immunoreactivities at the adult stage of EGF-treated mice, several reports indicate that postnatal GABAergic mal-development have substantial impact on later GABA functions (Belforte et al. 2010; Inan et al. 2013; Nawa et al. 2014) . In this respect, it remains to be explored how the postnatal impact of EGF challenges or GABAergic manipulation later results in the behavioral and pathophysiological deficits at the post-pubertal stage (Nakazawa et al. 2012). We have been analyzing EGF-treated rats as an animal model for schizophrenia and demonstrated the structural and functional abnormalities in their basal ganglia circuits as well as in the dopamine system (Futamura et al. 2003; Tohmi et al. 2005; Sotoyama et al. 2011 Sotoyama et al. , 2013 . However, the present results suggest the behavioral deficits found in the EGF-treated animals may also involve the GABAergic neuropathology or pathophysiology.
Conclusion
This study shows that exogenous EGF signals attenuate phenotypic development and synaptic function of the subpopulation of GABAergic neurons in rodent fontal cortex. The observed activity of EGF highly contrasted with the known neurotrophic actions of NRG1. Our findings first verify a negative role of ErbB1 signals for GABAergic development or maturation in the neocortex.
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